2.245USD+1.58%Mkt Cap: 8.14M USDP/E: —Last update: 2026-05-26
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap8.14M USD
Enterprise Value3.27M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-8.77M USD
Revenue/Share—
Last Price2.245 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS29405E2081
Valuation
P/E (Trailing)—
P/E (Forward)-1.57
PEG—
EV/EBITDA-0.41
EV/Revenue—
P/S—
P/B0.56
EPS (TTM)-22.74
EPS (Forward)-1.41
52W Range
1.7103% of range17.64
52W High17.64 USD
52W Low1.710 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-209.98%
ROA-172.14%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.14M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-59.03%
Net Debt-4.91M USD
Net Debt/EBITDA0.61
Balance Sheet
Debt/Equity—
Current Ratio11.67
Quick Ratio10.66
Book Value/Sh3.935 USD
Cash/Share1.333 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateApr 23, 2008
Pay DateNov 25, 2019
Splits
Last Split1:12
Split DateOct 28, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.3.68M
Float3.61M
Insiders2.15%
Institutions4.05%
Short Interest
Short Ratio0.1d
Short % Float45.70%
Short % Out.44.65%
Shares Short886.51K
Short (prev mo.)70.70K
Technical
SMA 502.634 (-14.8%)
SMA 2005.714 (-60.7%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)7.93M
Avg Vol (10d)259.35K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—